Market Readiness Commercial-stage precision oncology company with FDA approval for IsoPSA in vitro diagnostic kit; strong near-term sales potential as a nationwide lab deployment accelerates.

Growth Trajectory Recent CEO appointment and board additions signal active commercial expansion and governance support, aligning with aggressive go-to-market efforts and potential channel partnerships.

Funding Strength Substantial funding history plus a mid six-figure to low seven-figure revenue range indicate financial runway to scale sales teams, clinical validation, and marketing campaigns.

Prostate Focus IsoPSA launch and targeted prostate cancer campaigns create cross-sell opportunities within oncology diagnostics and potential collaboration with urology and pathology labs.

Tech & Ops Readiness Robust tech stack and enterprise tools (Azure, Intune, DocuSign, 365) support scalable customer onboarding, digital contracting, and secure data flows for large lab networks.